罗泊替尼

罗泊替尼（CAS 1802220-02-5）的独立参考数据，整理自公开化学数据库。

各数据库的登记标识

计算分子描述符

在册的记载用途

Repotrectinib is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). It is also indicated in patients ≥12 years of age and older with neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive solid tumors which are locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have experienced disease progression following treatment or have no satisfactory alternative.Repotrectinib is a small molecule inhibitor of the proto-oncogene tyrosine-protein kinase ROS1 and of tropomyosin receptor tyrosine kinases (TRK-A, -B and -C) and is used to treat adults with non-small cell lung cancer. Repotrectinib is associated with a moderate rate of mild transient elevations in serum aminotransferase levels during therapy but has not been linked to episodes of clinically apparent liver injury with jaundice.

同义词与商品名

Repotrectinib; 1802220-02-5; TPX-0005; Augtyro; 08O3FQ4UNP; repotrectinibum; (3R,6S,)-45-FLUORO-3,6-DIMETHYL-5-OXA-2,8-DIAZA-1(5,3)-PYRAZOLO(1,5-A)PYRIMIDINA-4(1,2)-BENZENANONAPHAN-9-ONE; (3R,6S,)-45-Fluoro-3,6-dimethyl-5-oxa-2,8-diaza-1(5,3)-pyrazolo[1,5-a]pyrimidina-4(1,2)-benzenanonaphan-9-one; RefChem:178876; Multikinase Inhibitor TPX-0005; Multi-kinase Inhibitor TPX-0005; ALK/ROS1/NTRK/SRC/FAK Multikinase Inhibitor TPX-0005; Ropotrectinib; Repotrectinib [USAN]; TPX0005; Repotrectinib(TPX-005)

公开数据库对它的描述

Ropotrectinib · CAS 1802220-02-5 · C18H18FN5O2. UNII 08O3FQ4UNP.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。